ALGN vs PDEX vs XRAY Stock Comparison

Align Technology, Pro Dex and Dentsply Sirona Prices as of Nov 13, 2026 Peers: Industry group
ALGN Align Technology Inc
$168.32 +16.5% 1M +20.7% 1Y
Market cap
$11.88B
P/E
24.2x
Revenue (TTM)
$4.16B
Div. yield
–
Dental Healthcare
2 wins
PDEX Pro Dex Inc
$65.66 +9.8% 1M +106.2% 1Y
Market cap
$209.64M
P/E
17.4x
Revenue (TTM)
$79.58M
Div. yield
–
Medical Devices Healthcare
8 wins

Head to Head

11 decided of 12

Pro Dex leads on 8 of the 12 questions below (Pro Dex 8, Align Technology 2, Dentsply Sirona 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALGNPDEXXRAYLeader
Larger companyMarket capitalisation $11.88B $209.64M $1.80B ALGN
Cheaper on earningsLower P/E, profitable companies only 24.2x 17.4x -14.9x PDEX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 15.5x 20.3x 6.8x XRAY
Faster revenue growthRevenue growth, trailing twelve months +4.4% +13.3% -1.4% PDEX
More profitableNet margin, trailing twelve months 11.8% 15.1% -3.4% PDEX
Better return on capitalReturn on invested capital — 12.9% -1.5% PDEX
Less leveragedLower net debt / EBITDA — 1.3x 7.1x PDEX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +20.7% +106.2% -16.3% PDEX
Better 5-year returnAnnualised price return, 5 years -24.6%/yr +23.1%/yr -30.1%/yr PDEX
Less volatileAnnualised volatility, 1 year 40.3% 55.2% 48.1% ALGN
Higher overall scoreMean of the five percentile scores vs peers 70/100 82/100 63/100 PDEX

Percentile Scorecard

ALGNPDEXXRAY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALGNPDEXXRAY
Valuation 85 #37 of 243 84 #41 of 243 93 #17 of 243
Growth 38 #142 of 228 91 #21 of 228 51 #112 of 228
Profitability 87 #29 of 222 91 #21 of 222 67 #73 of 222
Financial Health 48 #130 of 248 62 #96 of 248 15 #211 of 248
Shareholder Returns 92 #13 of 158 82 #30 of 158 86 #23 of 158
Overall 70 82 63
  • ALGN ranked among 252 companies in Medical Devices and Diagnostics
  • PDEX ranked among 252 companies in Medical Devices and Diagnostics
  • XRAY ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALGNPDEXXRAYSPY
1 month +16.5%+9.8%+8.5% -2.0%
3 months -7.2%-2.0%-21.0% -2.8%
6 months +7.0%+10.8%-9.0% +2.0%
Year to date +7.8%+70.6%-19.9% +10.6%
1 year +20.7%+106.2%-16.3% +12.2%
3 years -17.0%+264.4%-68.3% +68.1%
3 years, per year -6.0%+53.9%-31.9% +18.9%
5 years -75.5%+182.3%-83.3% +61.4%
5 years, per year -24.6%+23.1%-30.1% +10.1%
10 years +83.9%+1,359.1%-84.8% +248.5%
10 years, per year +6.3%+30.7%-17.2% +13.3%

Risk

MeasureALGNPDEXXRAYSPY
Volatility, 1Y 40.3%55.2%48.1% 13.6%
Downside volatility, 1Y 37.6%51.2%45.6% 13.9%
Beta vs S&P 500, 1Y 1.331.321.17 1.00
Return / volatility, 1Y 0.511.92-0.34 0.90
Max drawdown, 5Y -82.0%-65.4%-85.7% -25.4%
From 52-week high -14.8%-10.6%-37.6% -3.2%
52-week high $197.51$73.41$14.68 $779.14
52-week low $132.28$28.91$8.42 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALGNPDEXXRAY
P/E now vs peer median 24.3xmedian 26.5x 17.5xmedian 26.5x -15.1xmedian 26.5x
P/S now vs peer median 2.9xmedian 2.7x 2.6xmedian 2.7x 0.5xmedian 2.7x
EV/EBITDA now vs peer median 12.5xmedian 18.4x 15.5xmedian 18.4x 13.5xmedian 18.4x
P/FCF now vs peer median 19.7xmedian 25.4x 19.7xmedian 25.4x 17.6xmedian 25.4x
P/B now vs peer median 2.8xmedian 2.5x 4.3xmedian 2.5x 1.3xmedian 2.5x
PEG now vs peer median 1.78median 0.98 0.50median 0.98 -0.97median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALGNPDEXXRAY
Revenue $4.16B $79.58M $3.58B
Gross profit $2.88B $25.82M $1.81B
Operating income $620.46M $13.40M -$55.00M
Net income $491.87M $12.03M -$122.00M
Free cash flow $602.50M $10.69M $103.00M
R&D $377.60M $3.79M $171.00M
EPS (diluted) $6.93 $3.63 $-0.61
Cash & equivalents $1.14B $11.76M $195.00M
Total debt – $32.92M $2.20B
Shares (diluted) 71.02M 3.32M 199.20M
Enterprise value $7.48B $173.56M $851.76M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALGNPDEXXRAY
P/E 24.3x 17.5x -15.1x
P/FCF 19.7x 19.7x 17.6x
P/Operating cash flow 15.9x 18.4x 6.7x
P/S 2.9x 2.6x 0.5x
P/B 2.8x 4.3x 1.3x
P/Tangible book 2.8x 4.3x 3.4x
EV/EBITDA 12.5x 15.5x 13.5x
EV/EBIT 17.3x 17.2x -69.5x
EV/Revenue 2.6x 2.9x 1.1x
EV/FCF 17.8x 21.5x 37.1x
EV/Operating cash flow 14.3x 20.2x 14.0x
PEG (3Y EPS CAGR) 1.78 0.50 -0.97

Growth

14 metrics
MetricALGNPDEXXRAY
Revenue growth (1Y) 4.4% 13.3% -1.4%
Revenue CAGR (3Y) 3.0% 19.2% -3.2%
Gross profit growth (1Y) 5.5% 30.9% -2.0%
Gross profit CAGR (3Y) 2.7% 24.3% -4.6%
Operating income growth (1Y) 16.1% 24.2% 93.1%
Operating income CAGR (3Y) 2.0% 26.3% 16.1%
Net income growth (1Y) 30.0% 7.5% 86.2%
Net income CAGR (3Y) 10.7% 31.8% 17.7%
EPS growth (1Y) 32.6% 8.2% 86.3%
EPS CAGR (3Y) 13.6% 34.8% 15.6%
Operating cash flow growth (1Y) 14.3% 1,007% 23.1%
Operating cash flow CAGR (3Y) -5.3% 56.8% -8.8%
Free cash flow growth (1Y) 6.3% 592.2% 28.8%
Free cash flow CAGR (3Y) -4.2% 73.7% -22.1%

Profitability

14 metrics
MetricALGNPDEXXRAY
Gross margin 69.1% 32.5% 50.5%
EBITDA margin 20.6% 18.7% 7.9%
Operating margin 14.9% 16.8% -1.5%
Pretax margin 15.5% 19.1% -2.5%
Net margin 11.8% 15.1% -3.4%
FCF margin 14.5% 13.4% 2.9%
Operating cash flow margin 18.0% 14.4% 7.6%
Return on equity 11.5% 24.8% -9.0%
Return on assets 7.6% 15.9% -2.3%
Return on invested capital – 12.9% -1.5%
Return on capital employed 13.6% 21.4% -1.4%
Asset turnover 0.6x 1.1x 0.7x
Cash conversion (OCF / net income) 1.5x 0.9x -2.2x
Stock comp / revenue 4.1% 0.8% 0.9%

Financial Health

11 metrics
MetricALGNPDEXXRAY
Debt / assets – 43.0% 42.4%
Debt / equity – 0.7x 1.6x
Net debt / EBITDA – 1.3x 7.1x
Debt / FCF – 3.1x 21.4x
Liabilities / assets 34.0% 35.6% 73.9%
Equity / assets 66.0% 64.4% 26.1%
Interest coverage – 15.4x -0.6x
Current ratio 1.4x 4.2x 1.6x
Quick ratio 1.2x 2.4x 0.7x
Cash ratio 0.6x 1.0x 0.2x
Altman Z-score 4.89 7.79 0.70

Shareholder Returns

7 metrics
MetricALGNPDEXXRAY
Dividend yield – – 1.7%
Net buyback yield 2.3% 0.8% 0.7%
Shareholder yield 2.3% 0.8% 2.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALGNPDEXXRAY
Forward P/E 15.5xFY2026 20.3xFY2027 6.8xFY2026
EPS, next fiscal year $10.86FY2026 $3.24FY2027 $1.35FY2026
EPS growth, next FY +3.3%FY2026 -21.4%FY2027 -15.6%FY2026
EPS growth, the year after +16.6% -3.1% -1.5%
Revenue, next fiscal year $3.84BFY2026 $87.24MFY2027 $3.63BFY2026
Revenue growth, next FY -4.7%FY2026 +12.5%FY2027 -1.4%FY2026
Revenue growth, the year after +3.1% -6.8% +1.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALGNPDEXXRAY
Held by institutions 100.0% 22.8% 100.0%
Institutions holding 678 68 378
Change in shares held, QoQ +4.2% -1.8% +6.1%
Institutions buying 293 40 207
Institutions selling 268 20 116
Buyers to sellers 1.09 2.00 1.78

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALGNPDEXXRAY
ALGN 1.00 0.24 0.60
PDEX 0.24 1.00 0.18
XRAY 0.60 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALGN, PDEX and XRAY?

Align Technology (ALGN) is the largest by market capitalisation: Align Technology (ALGN) $11.88B, Pro Dex (PDEX) $209.64M, Dentsply Sirona (XRAY) $1.80B.

Which stock is cheaper, ALGN, PDEX and XRAY?

Pro Dex (PDEX) trades on the lowest price-to-earnings ratio (Align Technology (ALGN) 24.2x, Pro Dex (PDEX) 17.4x, Dentsply Sirona (XRAY) -14.9x). On next year's consensus earnings, Dentsply Sirona (XRAY) is cheapest (Align Technology (ALGN) 15.5x, Pro Dex (PDEX) 20.3x, Dentsply Sirona (XRAY) 6.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Pro Dex (PDEX) grew revenue fastest over the trailing twelve months: Align Technology (ALGN) +4.4%, Pro Dex (PDEX) +13.3%, Dentsply Sirona (XRAY) -1.4%.

Which company is more profitable?

Pro Dex (PDEX) has the highest net margin (Align Technology (ALGN) 11.8%, Pro Dex (PDEX) 15.1%, Dentsply Sirona (XRAY) -3.4%). On return on invested capital, Pro Dex (PDEX) leads (Pro Dex (PDEX) 12.9%, Dentsply Sirona (XRAY) -1.5%).

Which stock has performed better?

Over the past year Pro Dex (PDEX) returned the most: Align Technology (ALGN) +20.7%, Pro Dex (PDEX) +106.2%, Dentsply Sirona (XRAY) -16.3%. Over five years, Pro Dex (PDEX) compounded fastest (Align Technology (ALGN) -24.6%/yr, Pro Dex (PDEX) +23.1%/yr, Dentsply Sirona (XRAY) -30.1%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Align Technology (ALGN) has been the steadiest (Align Technology (ALGN) 40.3%, Pro Dex (PDEX) 55.2%, Dentsply Sirona (XRAY) 48.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALGN, PDEX and XRAY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Pro Dex (PDEX) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.